ClinicalTrials.gg

Program

evofosfamide

Also written as “TH-302”, “Evofosfamide” and “TH-302 combination with pemetrexed”.

Its studies are mostly in Sarcoma · Carcinoma, Non-Small-Cell Lung · Pancreatic Neoplasms · Prostatic Neoplasms · Melanoma, led by 3 companies.

Furthest: phase 3, since Sep 20, 201117 company-led studies, 1 open or runningNext primary completion: Oct 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Threshold Pharmaceuticals80 open or runningphase 3since Sep 20, 2011Jun 28, 2007none ahead
ImmunoGenesis71 open or runningphase 3since Dec 7, 2012Aug 26, 2008Oct 2027phase 2 · NCT06782555
Merck KGaA, Darmstadt, Germany20 open or runningphase 2since Sep 30, 2014Feb 20, 2014none ahead

Also a collaborator on its studies: Agenus and pra-health-sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Jun 28, 2007.

  1. Jun 1, 2010Phase 1 study in Leukemia, Myeloid, AcuteThreshold Pharmaceuticals · NCT01149915 · 40 enrolled · United States
  2. Jun 11, 2010Phase 2 study in Pancreatic AdenocarcinomaImmunoGenesis · NCT01144455 · 214 enrolled · United States
  3. Jun 23, 2011Phase 1 study in Gastrointestinal Stromal TumorsThreshold Pharmaceuticals · NCT01381822 · 58 enrolled · United States
  4. Sep 20, 2011Phase 3 study in SarcomaThreshold Pharmaceuticals · NCT01440088 · 640 enrolled · United States, Austria, Belgium and more
  5. Jan 6, 2012Phase 2 study in Multiple MyelomaThreshold Pharmaceuticals · NCT01522872 · 98 enrolled · United States
  6. Dec 7, 2012Phase 3 study in Neoplasm MetastasisImmunoGenesis · NCT01746979 · 693 enrolled · United States, Germany
  7. May 13, 2013Phase 2 study in MelanomaImmunoGenesis · NCT01864538 · 11 enrolled · United States, Canada
  8. Nov 14, 2013Phase 1 study in Solid TumorsThreshold Pharmaceuticals · NCT02020226 · 40 enrolled · United States
  9. Jan 24, 2014Phase 1 study in Pancreatic NeoplasmsImmunoGenesis · NCT02047500 · 19 enrolled · United States
  10. Feb 20, 2014Merck KGaA, Darmstadt, Germany's first study: phase 1 study in Solid TumorNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT02076230 · 10 enrolled · Germany
  11. Mar 18, 2014Phase 2 study in Carcinoma, Non-Small-Cell LungImmunoGenesis · NCT02093962 · 265 enrolled · United States, Czechia, Germany and more
  12. Sep 30, 2014Phase 2 study in SarcomaMerck KGaA, Darmstadt, Germany · NCT02255110 · 6 enrolled · Japan
  13. Mar 22, 2017Phase 1 study in Pancreatic NeoplasmsThreshold Pharmaceuticals · NCT03098160 · 69 enrolled · United States
  14. Jan 9, 2025Phase 2 study in Prostatic NeoplasmsImmunoGenesis · NCT06782555 · 71 enrolled · United States

Ahead

  1. Oct 2027Primary completion: phase 2 study in Prostatic NeoplasmsImmunoGenesis · NCT06782555

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06782555Prostatic Neoplasms · United States2Active, not recruitingImmunoGenesisOct 202771
NCT03098160Pancreatic Neoplasms · United States1UNKNOWNThreshold PharmaceuticalsJan 201969
NCT02255110Sarcoma · Japan2TerminatedMerck KGaA, Darmstadt, GermanyJan 12, 20166
NCT02093962Carcinoma, Non-Small-Cell Lung · United States, Czechia, Germany and more2TerminatedImmunoGenesisApr 2016265
NCT02076230Solid Tumor · Germany1CompletedMerck KGaA, Darmstadt, GermanySep 201410
NCT02047500Pancreatic Neoplasms · United States1TerminatedImmunoGenesisSep 201519
NCT02020226Solid Tumors · United States1UNKNOWNThreshold PharmaceuticalsJul 201640
NCT01864538Melanoma · United States, Canada2TerminatedImmunoGenesisSep 201511
NCT01746979Neoplasm Metastasis · United States, Germany3CompletedImmunoGenesisFeb 2016693
NCT01522872Multiple Myeloma · United States2UNKNOWNThreshold PharmaceuticalsSep 201698
NCT01440088Sarcoma · United States, Austria, Belgium and more3CompletedThreshold PharmaceuticalsDec 2015640
NCT01381822Gastrointestinal Stromal Tumors · United States1UNKNOWNThreshold PharmaceuticalsJun 201458
NCT01144455Pancreatic Adenocarcinoma · United States2CompletedImmunoGenesisSep 2013214
NCT01149915Leukemia, Myeloid, Acute · United States1CompletedThreshold PharmaceuticalsAug 201340
NCT00743379Carcinoma, Non-Small-Cell Lung · United States2CompletedThreshold PharmaceuticalsJul 201371
NCT00742963Sarcoma · United States2CompletedImmunoGenesisJul 2013107
NCT00495144Neoplasms · United States1CompletedThreshold PharmaceuticalsDec 2011129

How it is read

Names in the registry

  • “TH-302”, 13 entries
  • “Evofosfamide”, 2 entries
  • “TH-302 combination with pemetrexed”, 1 entry
  • “[14C] TH-302 (Label 1)”, 1 entry
  • “[14C] TH-302 (Label 2)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.